Ann Duerr Bio

Dr. Ann Duerr

Ann Duerr's research focuses on AIDS and HIV prevention, including novel vaccine strategies for induction of mucosal immunity, studies on antiretroviral therapy (ART), clinical trials in resource-poor settings and eludicating factors that help prevent sexual transmission of HIV.

HIV Vaccine Trials Network

Ann Duerr joined the HIV Vaccine Trials Network after 13 years at the Centers for Disease Control and Prevention, where she was Chief of the HIV Section in the Women's Health and Fertility Branch, conducting clinical-epidemiological research on HIV infection, particularly in relation to women's reproductive health. Her initial epidemiologic research focused on parameters associated with HIV transmission from women to infants in Rwanda and on fully characterizing the clinical course of HIV infections in US women. 

More recently, her work has been focused on prevention. Specifically, on an intervention among African women to prevent mother-to-child HIV transmission via breastfeeding and on trials of prophylactic HIV vaccines as Director for Scientific Affairs of the HIV Vaccine Trials Network (HVTN). She also conducts clinical studies and research in non-human primates investigating ways to increase vaccine-induced immunity at mucosal surfaces, the site of infection for most pathogens and is currently working on studies of antiretroviral treatment to prevent onward HIV transmission in Peru.

To learn more, please visit the HVTN website at

Dr. Ann Duerr presenting at Fred Hutch's Science Spectrum event, July 2009


20202019 | 2018 | 2017 | 2016 | 2015 | 2014 | 20132012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 and earlier


Gonzales P, Grieco A, White E, Ding R, Bender Ignacio R, Pinto-Santini D, Lama J, Altice F, Duerr A. Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy. PLoS One, 2020,; 32134956

Green D, Tordoff D, Kharono B, Akullian A, Bershteyn A, Morrison M, Garnett G, Duerr A, Drain P. Evidence of sociodemographic heterogeneity across the HIV care cascade and progress towards 90-90-90 in sub-Saharan Africa - a systematic review. J Int AIDS Soc. 2020 Mar;23(3):e25470. doi: 10.1002/jia2.25470, PMID 32153117

Lama J, Bender Ignacio R, Alfaro R, Rios J, Gallardo Cartagena J, Valdez R, Bain C, Sosa Barbaran K, Villaran M, Pilcher C, Gonzales P, Sanchez J, Duerr A. Clinical and Immunologic Outcomes after Immediate or Deferred Antiretroviral Therapy Initiation during Primary HIV Infection: The Sabes Randomized Clinical Study. Clin Infect Dis. 2020 Feb 28. pii: ciaa167. doi: 10.1093/cid/ciaa167; PMID 32107526

Lankowski A, Sánchez H, Hidalgo J, Cabello R, Duerr A. Sex-on-Premise Venue Attendance and Associated Sexual Risk Characteristics Among Men Who Have Sex with Men in Lima, Perú. BMC Public Health. 2020 Apr 19;20(1):521. PMID: 32306942

Curlin ME, Shao J, Diaz G, Eldefsen PT, Novak R, Mayer KH, Allen MA, Morgan C, Maenza J, Buchbinder S, Keefer M, Corey L, Duerr A, and the NIH HIV Vaccine Trials Network (HVTN). Long-term mucosal T-cell activation and homing phenotypes in recipients of an Ad5 vectored HIV vaccine. Vaccine in press


Molina, Y., Konda, K. A., Sanchez, H., de la Grecca, R., Villarán, M., Rios, J., Bain, C. E.,   Greer, A., Wandell, G., Lama, J. R., & Duerr, A. Perceptions Prediagnosis and Social Experiences Postdiagnosis Among a Sample of High-Risk Peruvian Men Who Have Sex With Men. Stigma and Health. 2019 May;4(2):204-212. doi: 10.1037/sah0000111.

Montaño MA, Dombrowski JC, Dasgupta S, Golden MR, Duerr A, Manhart LE, Barbee LA, Khosropour CM. Changes in Sexual Behavior and STI Diagnoses Among MSM Initiating PrEP in a Clinic Setting. AIDS Behav. 2019; 23:548-555.

Rinehart R, Rao D, Amico RK, Ruiz E, Brandes P, Correa C, Pasalar S, Lama JR, Duerr A,   & Molina Y. Experienced HIV-related stigma and psychological distress among Peruvian sexual and gender minorities: A longitudinal study to explore mediating roles of internalized  HIV-related stigma and coping styles. AIDS & Behavior. 2019;  23:661-674

Long J, Montaño M, Cabello R, Sanchez H, Lama JR, Duerr A. Comparing sexual risk behavior in a high-risk group of men who have sex with men and transgender women in Lima, Peru. J Acquir Immune Defic Syndr. 2019 Jan 9. PMID:30664074

Bender Ignacio, R. A., Dasgupta, S., Stevens-Ayers, T., Kula, T., Hill, J. A., Lee, S. J., Mielcarek, M., Duerr, A., Elledge, S., & Boeckh, M.  Comprehensive Virome-wide Antibody Responses by Systematic Epitope Scanning After Hematopoietic Cell Transplantation. Blood; 2019 .

Longino A, Montano MA, Sanchez H, Bayer A, Sanchez J, Tossas-Milligan K, Molina Y, Duerr A. Increasing PrEP Uptake and Adherence among MSM and TW Sex Workers in Lima, Perú: What and Whom Do Different Patients Trust? AIDS Care 2019 Jun 26:1-6. doi: 10.1080/09540121.2019.163478

Montaño MA, Dombrowski JC, Dasgupta S, Golden MR, Manhart LE, Barbee LA, Duerr A, Khosropour CM. Differences in STI Risk comparing PrEP users and propensity score-matched historical controls in a clinic setting. AIDS. 2019 May 29. doi: 0.1097/QAD.0000000000002281.

Green D, Kharono B, Tordoff DM, Akullian A, Bershteyn A, Morrison M, Garnett G, Duerr A, Drain P. Demographic and risk group heterogeneity across the UNAIDS 90-90-90 targets: a systematic review and meta-analysis protocol. Syst Rev. 2019 May 6;8(1):110. doi: 10.1186/s13643-019-1024-6.

Dimitrov D, Wood D, Ulrich A, Swan DA, Adamson B, Lama JR, Sanchez J, Duerr A. Projected effectiveness of HIV detection during early infection and rapid ART initiation among MSM and transgender women in Peru: A modeling study. Infect Dis Model. 2019 Apr 6;4:73-82. doi: 10.1016/j.idm.2019.04.001.

Ewing AC, Davis NL, Kayira D, Hosseinipour MC, van der Horst C, Jamieson DJ, Kourtis AP; Breastfeeding, Antiretrovirals and Nutrition study team. Prescription of Antibacterial Drugs for HIV-Exposed, Uninfected Infants, Malawi, 2004-2010. Emerg Infect Dis. 2019 Jan;25(1). doi: 10.3201/eid2501.180782.

Long J, Ulrich A, White E, Dasgupta S, Cabello R, Sanchez H, Lama J, Duerr A. Characterizing men who have sex with transgender women in Lima, Peru: Sexual behavior and partnership profiles. AIDS and Behavior, 2019 Jul 12. doi: 10.1007/s10461-019-02590-w.

Ulrich A, Sanchez J, Lama J, Manhart L, Goodreau S, Duerr A. Correlates of concurrent partnerships and patterns of condom use among men who have sex with men and transgender women in Peru. PLoS One, Sep 16;14(9):e0222114. doi: 10.1371

Trebelcock W, Lama JR, Duerr A, Sanchez H, Cabello R, Gilada T, Segura P, Reisner S, Mayer KH, Mullins J, Bender Ignacio R. HIV Pretreatment Drug Resistance Among Cisgender MSM and Transgender Women from Lima, Peru. JIAS, 2019, 22e25411, DOI:10.1002/jia2.25411

Chang Y, Sevekari T, Duerr A, Molina Y, Gilada T. “HIV Self-Testing in Pune, India: Perspectives and Recommendations of Female Sex Workers and Peer Educators” AIDS Care, 2019 Oct 31:1-4. doi: 10.1080/09540121.2019

Grebe E, Facente SN, Bingham J, Pilcher CD, Powrie A, Gerber J, Priede G, Chibawara T, Busch MP, Murphy G, Kassanjee R, Welte A; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool. BMC Infect Dis. 2019 Oct 26;19(1):894. doi: 10.1186/s12879-019-4543-9.


Molina Y, Ulrich A, Greer AC, Primbas A, Wandell G, Sanchez H, Bain C, Konda K, Clark J, de la Grecca R, Villaran M, Pasalar S, Lama JR, & Duerr A. 2018. Impact of pre-diagnosis awareness of HIV-related stigma and dispositional coping on linkage to HIV care among newly diagnosed HIV+ Peruvian patients. AIDS Care. 2018 January, DOI:10.1080/09540121.2018.1563282.

Lama JR, Brezak A, Dobbins JG, Sanchez H, Cabello R, Rios J, Bain C, Ulrich A, De la Grecca R, Sanchez J, Duerr A. Design Strategy of the Sabes Study: Diagnosis and Treatment of Early HIV Infection Among Men Who Have Sex With Men and Transgender Women in Lima, Peru, 2013-2017. Am J Epidemiol. 2018 Aug 1;187(8):1577-1585. doi: 10.1093/aje/kwy030.


Seaton KE, Vandergrift NA, Deal AW, Rountree W, Bainbridge J, Grebe E, Anderson DA, Sawant S, Shen X, Yates NL, Denny TN, Liao HX, Haynes BF, Robb ML, Parkin N, Santos BR, Garrett N, Price MA, Naniche D, Duerr AC; CEPHIA group, Keating S, Hampton D, Facente S, Marson K, Welte A, Pilcher CD, Cohen MS, Tomaras GD. Computational analysis of antibody dynamics identifies recent HIV-1 infection. JCI Insight. 2017 Dec 21;2(24). pii: 94355. doi: 10.1172/jci.insight.94355. [Epub ahead of print]

Davis NL, Wiener J, Juliano JJ, Adair L, Chasela CS, Kayira D, Hudgens MG, van der Horst C, Jamieson DJ, Kourtis AP; Breastfeeding, Antiretrovirals and Nutrition (BAN) Study Team; Breastfeeding, Antiretrovirals and Nutrition (BAN) Study Team. Co-trimoxazole Prophylaxis, Asymptomatic Malaria Parasitemia, and Infectious Morbidity in Human Immunodeficiency Virus-Exposed, Uninfected Infants in Malawi: The BAN Study. Clin Infect Dis. 2017 Aug 15;65(4):575-580. doi: 10.1093/cid/cix367.

Vagenas P, Brown SE, Clark JL, Konda KA, Lama JR, Sánchez J, Duerr AC, Altice FL. A Qualitative Assessment of Alcohol Consumption and Sexual Risk Behaviors Among Men Who Have Sex With Men and Transgender Women in Peru. Subst Use Misuse. 2017 Jun 7;52(7):831-839. doi: 10.1080/10826084.2016.1264968. Epub 2017 Feb 7.

Wandell GM, Molina Y, Sánchez H, Greer AC, Ríos J, Bain C, Segura P, Lama JR, Sánchez J, Duerr A. Knowledge and preferences concerning acute HIV testing programs among both Peruvian men who have sex with men and transgender women. Int J STD AIDS. 2017 Sep;28(10):1010-1017. doi: 10.1177/0956462416685674. Epub 2017 Jan 6.

Murphy G, Pilcher CD, Keating SM, Kassanjee R, Facente SN, Welte A, Grebe E, Marson K, Busch MP, Dailey P, Parkin N, Osborn J, Ongarello S, Marsh K, Garcia-Calleja JM; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). Moving towards a reliable HIV incidence test - current status, resources available, future directions and challenges ahead. Epidemiol Infect. 2017 Apr;145(5):925-941. doi: 10.1017/S0950268816002910. Epub 2016 Dec 22. Review.


Hayes PJ, Cox JH, Coleman AR, Fernandez N, Bergin PJ, Kopycinski JT, Nitayaphan S, Pitisuttihum P, de Souza M, Duerr A, Morgan C, Gilmour JW. Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition. AIDS. 2016 Jul 17;30(11):1703-12. doi: 10.1097/QAD.0000000000001122.


Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.

Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M. HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nat Med. 2015 Oct;21(10):1139-41. doi: 10.1038/nm.3932. Epub 2015 Aug 31.

Beyrer C, Birx DL, Bekker LG, Barré-Sinoussi F, Cahn P, Dybul MR, Eholié SP, Kavanagh MM, Katabira ET, Lundgren JD, Mworeko L, Pala M, Puttanakit T, Ryan O, Sidibé M, Montaner JS; Vancouver Consensus Signatories. The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. Lancet. 2015 Aug 8;386(9993):505-7. doi: 10.1016/S0140-6736(15)61458-1. No abstract available.

Flax VL, Adair LS, Allen LH, Shahab-Ferdows S, Hampel D, Chasela CS, Tegha G, Daza EJ, Corbett A, Davis NL, Kamwendo D, Kourtis AP, van der Horst CM, Jamieson DJ, Bentley ME; BAN Study Team. Plasma Micronutrient Concentrations Are Altered by Antiretroviral Therapy and Lipid-Based Nutrient Supplements in Lactating HIV-Infected Malawian Women. J Nutr. 2015 Aug;145(8):1950-7. doi: 10.3945/jn.115.212290. Epub 2015 Jul 8.

Brown SE, Vagenas P, Konda KA, Clark JL, Lama JR, Gonzales P, Sanchez J, Duerr AC, Altice FL. Men Who Have Sex With Men in Peru: Acceptability of Medication-Assisted Therapy for Treating Alcohol Use Disorders. Am J Mens Health. 2017 Jul;11(4):1269-1278. doi: 10.1177/1557988315576775. Epub 2015 Mar 17.

Widen EM, Bentley ME, Chasela CS, Kayira D, Flax VL, Kourtis AP, Ellington SR, Kacheche Z, Tegha G, Jamieson DJ, van der Horst CM, Allen LH, Shahab-Ferdows S, Adair LS; BAN Study Team. Antiretroviral Treatment Is Associated With Iron Deficiency in HIV-Infected Malawian Women That Is Mitigated With Supplementation, but Is Not Associated With Infant Iron Deficiency During 24 Weeks of Exclusive Breastfeeding. J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):319-28. doi: 10.1097/QAI.0000000000000588. Erratum in: J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):e184.

Sellers CJ, Lee H, Chasela C, Kayira D, Soko A, Mofolo I, Ellington S, Hudgens MG, Kourtis AP, King CC, Jamieson DJ, van der Horst C; BAN Study Team. Reducing lost to follow-up in a large clinical trial of prevention of mother-to-child transmission of HIV: the Breastfeeding, Antiretrovirals and Nutrition study experience. Clin Trials. 2015 Apr;12(2):156-65. doi: 10.1177/1740774514562031. Epub 2014 Dec 17.


Huang Y, Duerr A, Frahm N, Zhang L, Moodie Z, De Rosa S, McElrath MJ, Gilbert PB. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study. PLoS One. 2014 Nov 4;9(11):e108631. doi: 10.1371/journal.pone.0108631. eCollection 2014.

Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L; HVTN 503/Phambili study team. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014 May;14(5):388-96. doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20.


Semprini AE, Macaluso M, Hollander L, Vucetich A, Duerr A, Mor G, Ravizza M, Jamieson DJ. Safe conception for HIV-discordant couples: insemination with processed semen from the HIV-infected partner. Am J Obstet Gynecol. 2013 May;208(5):402.e1-9. doi: 10.1016/j.ajog.2013.02.009. Epub 2013 Feb 8.

Gray GE, Metch B, Churchyard G, Mlisana K, Nchabeleng M, Allen M, Moodie Z, Kublin J, Bekker LG; HVTN 503 team. Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa? Vaccine. 2013 Apr 12;31(16):2089-96. doi: 10.1016/j.vaccine.2013.01.031. Epub 2013 Jan 29.

Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, Frey SE, Keefer MC; MVA Cardiac Safety Working Group. Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review. PLoS One. 2013;8(1):e54407. doi: 10.1371/journal.pone.0054407. Epub 2013 Jan 17.

Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Huang Y, Gilbert P, Corey L, Robertson MN. Reply to Richie and Villasante. J Infect Dis. 2013 Feb 15;207(4):690-2. doi: 10.1093/infdis/jis738. Epub 2012 Nov 29. No abstract available.

Parker ME, Tembo M, Adair L, Chasela C, Piwoz EG, Jamieson DJ, Ellington S, Kayira D, Soko A, Mkhomawanthu C, Martinson F, van der Horst CM, Bentley ME; BAN Study Team. The health of HIV-exposed children after early weaning. Matern Child Nutr. 2013 Apr;9(2):217-32. doi: 10.1111/j.1740-8709.2011.00369.x. Epub 2011 Nov 20.


Saganic L, Carr J, Solorio R, Courogen M, Jaenicke T, Duerr A. Comparing Measures of Late HIV Diagnosis in Washington State. AIDS Research and Treatment. Volume 2012 (2012), Article ID 182672, doi:10.1155/2012/182672

Duerr A. HIV treatment as prevention: next steps. Curr Opin HIV AIDS. 2012 Mar; 7:97-8. Erratum in: Curr Opin HIV AIDS. 2012 May;7:289

Duerr A, Huang Y, Buchbinder S, Coombs R, Lawrence D, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson M for the Step/ HVTN 504 study team. Extended follow-up of participants in a cell-mediated immunity HIV vaccine trial (Step study): Vaccine effect on HIV acquisition among men wanes over time. J Infect Dis, 2012; 206:258-266. Epub 2012 May 4.

Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, Krishnamurty AT, Chang JT, Adams DJ, Hensley TR, Salter AI, Morgan CA, Duerr AC, De Rosa SC, Aderem A, McElrath MJ. Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):E3503-12. doi: 10.1073/pnas.1208972109. Epub 2012 Nov 14.

Duerr A, Altice FL, Harries AD, Sohn AH. Antiretroviral treatment in resource-limited settings 2012. AIDS Res Treat. 2012;2012:346708. doi: 10.1155/2012/346708. Epub 2012 Jul 25. No abstract available.

Chasela CS, Wall P, Drobeniuc J, King CC, Teshale E, Hosseinipour MC, Ellington SR, Codd M, Jamieson DJ, Knight RJ, Fitzpatrick P, Kourtis AP, Hoffman IF, Kayira D, Mumba N, Kamwendo DD, Martinson F, Powderly W, van der Horst C, Kamili S; BAN team. Prevalence of hepatitis C virus infection among human immunodeficiency virus-1-infected pregnant women in Malawi: the BAN study. J Clin Virol. 2012 Aug;54(4):318-20. doi: 10.1016/j.jcv.2012.05.003. Epub 2012 Jun 2.


Kingkeow D, McNicholl J, Maneekarn N, Wongtakul J, Taechareonkul S, Suriyanon V, . Nelson K, Duerr A and Makonkawkeyoon S. Frequencies of IL10 SNP genotypes by multiplex PCRSSP and their association with viral load and CD4 counts in HIV-1-infected Thais. Asian Pac J Allergy Immunol 2011;29:94-101

Duerr A, Gallo M, Warner L, Jamieson DJ, Kulczycki A, Macaluso M. Assessing male condom failure and incorrect use. Sexually Trans Dis. 2011; 38:580-62011 [Jan 2011: Epub ahead of print]

Fitzgerald DW, Janes H, Robertson M, Coombs R, Frank I, Gilbert P, Loufty M, Mehrotra D, Duerr A; for the Step Study Protocol Team. An Ad5-Vectored HIV-1 Vaccine Elicits Cell-mediated Immunity but does not Affect Disease Progression in HIV-1-infected Male Subjects: Results From a Randomized Placebo-Controlled Trial (The Step Study). J Infect Dis. 2011; 203:765-772.

Curlin ME, Cassis-Ghavami F, Magaret AS, Spies GA, Duerr A, Celum CL, Sanchez JL, Margolick JB, Detels R, McElrath MJ, Corey L. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS. 2011; 25:153-8.

Rolland M, Tovanabutra S, Decamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A, O'Sullivan A, Crossler J, Jones T, Nau M, Wong K, Zhao H, Raugi DN, Sorensen S, Stoddard JN, Maust BS, Deng W, Hural J, Dubey S, Michael NL, Shiver J, Corey L, Li F, Self SG, Kim J, Buchbinder S, Casimiro DR, Robertson MN, Duerr A, McElrath MJ, McCutchan FE, Mullins JI. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011; 17:366-71

Migueles S, Rood J, Berkley A, Guo T, Mendoza D, Patamawenu A, Hallahan C, Cogliano-Shutta N, Frahm N, Duerr A, McElrath J and Connors M. Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles. PLoS Pathog. 2011;7(2):e1002002.

Frahm N, DeCamp A, Friedrich D, Carter D, Defawe O, Kublin J, Casimiro D, Duerr A, Robertson M, Buchbinder S, Huang Y, Spies G, De Rosa S, McElrath J. Adenovirus-specific T cells target regions conserved across multiple serotypes and modulate insert-specific immunity following MRKAd5/HIV-1 vaccination. J Clin Invest. 2012 Jan 3;122(1):359-67. doi: 10.1172/JCI60202. Epub 2011 Dec 27.


Cheng C, Gall J, Nason M, King CR, Koup R, Roederer M, McElrath J, Churchyard G, Morgan C, Duerr A, Baden L, Keefer M, Graham B, Nabel G. Differential specificity and immunogenicity of adenovirus 5 neutralizing antibodies elicited by natural infection or immunization. J Virol. 2010; 84:630-8.

Theiler R, Farr S, Karon J, Paramsothy P, Viscidi R, Duerr A, Cu-Uvin S, Sobel J, Shah K, Klein RS, and Jamieson DJ. High-Risk Human Papillomavirus Reactivation in Human Immunodeficiency Virus–Infected Women: Risk Factors for Cervical Viral Shedding. Obstet Gynecol 2010; 115:1150–8.

Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, Smith C, Ginsberg R, Eldridge J, Duerr A, Fast P, Haynes BF, and the AIDS Vaccine Evaluation Group. Immunization with cocktail of HIV-derived peptides in Montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS ONE 2010; 5(8): e11995.

Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, Martinson F, Tegha G, Knight RJ, Ahmed YI, Kamwendo DD, Hoffman IF, Ellington SR, Kacheche Z, Soko A, Wiener JB, Fiscus SA, Kazembe P, Mofolo IA, Chigwenembe M, Sichali DS, van der Horst CM; BAN Study Group. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010 Jun 17;362(24):2271-81

Farr SL, Nelson JA, Ng'ombe TJ, Kourtis AP, Chasela C, Johnson JA, Kashuba AD, Tegha GL, Wiener J, Eron JJ, Banda HN, Mpaso M, Lipscomb J, Matiki C, Fiscus SA, Jamieson DJ, van der Horst C; BAN Study Team. Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. J Acquir Immune Defic Syndr. 2010 Aug 15;54(5):515-23.

Nussenblatt RB, Bielekova B, Childs R, Krensky A, Strober W, Trinchieri G; Center for Human Immunology, Autoimmunity and Inflammation, National Institutes of Health. National Institutes of Health Center for Human Immunology Conference, September 2009. Ann N Y Acad Sci. 2010 Jul;1200 Suppl 1:E1-23.

Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson M, Mehrotra D, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead LS, Casimiro D, Hammer SM. Safety and Immunogenicity of the MRKAd5 gag HIV-1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Res Hum Retroviruses. 2010 Sep 20. [Epub ahead of print]

Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS. 2010 Sep;5(5):357-61.

Duerr A. Update on mucosal HIV vaccine vectors. Curr Opin HIV AIDS. 2010 Sep;5(5):397-403


Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV, Rompalo AM, Cu-Uvin S, Duerr A. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009; 113:26-31

Anderson DJ, Williams DL, Ballagh SA, Barnhart K, Creinin MD, Newman DR, Bowman FP, Politch JA, Duerr AC, Jamieson DJ. Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am J Reprod Immunol 2009; 61:121-9.

Ferguson YO, Eng E, Bentley M, Sandelowski M, Steckler A, Randall-David E, Piwoz EG, Zulu C, Chasela C, Soko A, Tembo M, Martinson F, Tohill BC, Ahmed Y, Kazembe P, Jamieson DJ, van der Horst C; UNC Project BAN Study Team. Evaluating nurses' implementation of an infant-feeding counseling protocol for HIV-infected mothers: The Ban Study in Lilongwe, Malawi. AIDS Educ Prev. 2009; 21:141-55

MacLachlan E, Mayer KH, Barnabas R, Sanchez J, Koblin B, Duerr A. The potential role of biomarkers in HIV preventive vaccine trials. JAIDS 2009; 51:536-45


Jaspan HB, Cunningham CK, Tucker TJ, Wright PF, Self SG, Sheets RL, Rogers AS, Bekker LG, Wilson CM, Duerr A, Wasserheit JN; the HIV Vaccine Adolescent Trials Working Group. Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads. JAIDS 2008; 47:86-92.

Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu SL, Johnson RP, Lifson J, Montefiori D, Moore J, Robert-Guroff M, Robinson H, Self S, Corey L. The Use of Nonhuman Primate Models in HIV Vaccine Development, PLoS Med 2008; 5(8): e173 doi:10.1371/journal.pmed.0050173

Van der Horst CM, Chasela C, Ahmed Y, Hoffman I, Hosseinipour M, Knight R, Fiscus S, Hudgens M, Kazembe P, Bentley M, Adair L, Piwoz E, Martinson F, Duerr A, Kourtis A, Loeliger E, Tohill B, Ellington S, and Jamieson D for the BAN Study team. Modifications of a large HIV prevention clinical trial to fit changing realities: A case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) Protocol in Lilongwe, Malawi. Contemporary Clinical Trials 2008; 30:24-33.

Sunderam S, Hollander L, Macaluso M, Vucetich A, Jamieson DJ, Osimo F, Duerr A, Semprini AE. Safe conception for HIV discordant couples through sperm-washing: experience and perceptions of patients in Milan, Italy. Reproductive Health Matters. 2008;16(31):211-9

Geise R, Connolly N, Duerr A. Emerging strategies in HIV prevention. Infections in Medicine, 2008.

Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; the Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet, 2008; 372:1881-93


Corneli A, Piwoz E, Bentley M, Moses A, Nkhoma J, Tohill B, Adair L, Mtimuni B, Ahmed Y, Duerr A, Kazembe P, van der Horst C for the UNC Project BAN Study Team. Involving communities in the design of clinical trial protocols: The BAN Study in Lilongwe, Malawi. Contemp Clin Trials 2007;28:59-67.

Follmann D, Duerr A, Tabet S, Gilbert P, Moodie Z, Fast, P, Cardinali M, Self, S: for the Workshop participants. Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop. JAIDS 2007;44:49-60.

Quayle A, Kourtis A, Cu-Uvin S, Politch J, Yang H, Bowman F, Shah M, Anderson D, Crowley-Nowick M, Duerr A. T lymphocyte profile and antibody concentration in the cervix of human immunodeficiency virus-1-infected women. JAIDS 2007;44:292-8.

Massad S, Fazzari M, Shah KS, Anastos K, Burk R, Klein RS, Minkoff H, Jamieson D, Duerr A, Celentano D, Gange S, Cu-Uvin S, Young M, Watts DH, Levine AM, Schuman P, Harris TG, Strickler HD. Outcomes after treatment for cervical intraepithelial neoplasia among women with human immunodeficiency virus. Lower Gen Tract Dis 2007;11:90-7.

Tohill B, Heilig CM, Klein RS, Rompalo A, Cu-Uvin S, Piwoz E, Jamieson D, Duerr A. Nutritional biomarkers associated with gynecological conditions among U.S. women with or at risk of HIV infection. Am J Clin Nutrit 2007;85:1327-34.

Kourtis A, Ibegbu C, Theiler R, Xu T, Bansil P, Jamieson DJ, Lindsay M, Butera S, Duerr A. Breast milk CD4+ T cells express high levels of CCR5 and CXCR4 and are preserved in HIV infected mothers on HAART. JID 2007;195:965-72.

Chen M, Macaluso M, Blackwell R, Galvao L, Kulczycki A, Diaz J, Jamieson DJ, Duerr A. Self-reported mechanical problems during condom use and semen exposure: comparison of two randomized trials in the United States of America and Brazil. Sex Transm Dis 2007;34:557-62.

Macaluso M, Blackwell R, Jamieson DJ, Kulczycki A, Chen MP, Akers R, Kim D, Duerr A. Efficacy of the male latex condom and of the female polyurethane condom as barriers to semen during intercourse: a randomized clinical trial. Am J Epi 2007;166:88-96.

Nelson KE, Costello C, Suriyanon V, Sennum S, Duerr A. Survival of blood donors and their spouses with HIV-1 Subtype E (CRF01 A_E) in Northern Thailand, 1992-2007. AIDS 2007;S6:47-54


Anderson J, Paramsothy P, Heilig C, Jamieson D, Shah KS, Duerr A. Accuracy of Papanicolaou test in HIV-infected women. Clin Infect Dis 2006;42:562-8.

Vernazza P, Hollander L, Semprini E, Anderson D, Duerr A. HIV-discordant couples and parenthood: how are we dealing with the risk of transmission? AIDS 2006;20:635-6.

Duerr A, Paramsothy P, Jamieson DJ, Cu-Uvin S, Schumann P, Klein RS, Anderson J. Effect of HIV infection on atypical squamous cells of undetermined significance. Clin Infect Dis 2006;42:855-61.

Grant A, Jamieson D, Elam-Evans L, Beck-Sague C, Duerr A, Henderson S. Reasons for testing and clinical and demographic profile of adolescents with non-perinatally acquired HIV infection. Pediatrics 2006;117:468-75.

Jamieson D, Paramsothy P, Cu-Uvin S, Duerr A. Vulvar, vaginal, and perianal intraepithelial neoplasia among women with and at risk for human immunodeficiency virus. Obstet & Gynecol 2006;107:1023-8.

Koshiol J, Schroeder J, Jamieson J, Marshall SW, Duerr A, Heilig CM, Shah KV, Klein RS, Cu-Uvin S, Schuman P, Celentano, Smith JS. Smoking and time to clearance of human papillomavirus (HPV) infection in HIV-seropositive and HIV-seronegative women. Am J Epi 2006;164:176-83.

Koshiol J, Schroeder J, Jamieson J, Marshall SW, Duerr A, Heilig CM, Shah KV, Klein RS, Cu-Uvin S, Schuman P, Celentano, Smith JS. Time to clearance of human papillomavirus (HPV) infection by HPV type in HIV-seropositive and HIV-seronegative women. Int J Cancer 2006;119:1623-9.

Duerr A, Wasserheit J, Corey L. HIV vaccines: New frontiers in vaccine development. Clin Infect Dis 2006;43:500-11.

Li F, Malhotra U, Gilbert P, Hawkins N, Duerr A, McElrath J, Corey L, Self S. Peptide selection for human immunogenicity virus type 1 CTL-based vaccine evaluation. Vaccine 2006;24:6893-904.

Barreiro P, Duerr A, Beckerman K, Soriano V. Reproductive options for HIV-serodiscordant couples. AIDS Reviews 2006;8:158-70.

Djomand G, Duerr A, Faulhaber JC, Struchiner CJ, Pacheco AC, Barroso PF, Melo MF, Schechter M. Post-seroconversion viral load trajectory in Brazil. JAIDS 2006; 43:401-4.

Wecker M, Ridzon R, Graham S, Duerr A. Strategies for global HIV prevention. Future Virology 2006;1:759-67.


Ghanem K, Shah N, Klein RS, Mayer K, Sobel J, Warren D, Jamieson D, Duerr A, Rompalo A for the HIV Epidemiology Research Group. The influence of sex hormones, HIV status and concomitant sexually transmitted infection on the inflammatory cell content of cervico-vaginal lavage fluid. J Infect Dis 2005;191:358-66.

Posner S, Kerimova J, Aliyeva F, Duerr A. Strategies for diagnosis of bacterial vaginosis in a resource-poor setting. Int J STD AIDS 2005;16:52-5.

Farley T, Mwachari C, Cohen C, Chipato T, Jaisamrarn U, Kiriwat O, Duerr A. Effect of contraceptive methods on natural history of HIV: studies from the Mombasa cohort. J Acquir Immune Defic Syndr 2005;38:S20-S21.

Costello C, Nelson K, Jamieson D, Spacek L, Sennun S, Tovanabutra S, Rungruengthanakit K, Suriyanon V, Duerr A. Predictors of low CD4 count and decreased HIV-1 survival in resource-limited settings: based on an antiretroviral naïve, heterosexual Thai population. JAIDS 2005;39:242-8.

Paramsothy P, Crouse C, Ahmed, Duerr A, Davis X, Jamieson D. Do women with HIV infection have different indications for hysterectomy? JAIDS 2005;39:378-9.

Duerr A, Hurst S, Kourtis A, Rutenberg N, Jamieson D. Integrating family planning and mother-to-child HIV transmission in resource-limited settings. Lancet 2005;366:261-3.

De Bruyn G, Hudgens M, Sullivan P, Duerr A for the HIV Vaccine Trials Network. Participant retention in clinical trials of candidate HIV-1 vaccines. JAIDS 2005;39:499-501.

Costello C, Nelson KE, Suriyanon V, Sennun S, Tovanabutra S, Heilig CM, Shiboski S, Jamieson DJ, Robison V, Rungruenthanakit K, Duerr A. HIV subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol 2005;34:577-84.


Paramsothy P, Duerr A, Heilig C, Cu-Uvin S, Anderson J, Schuman P, Klein RS. Abnormal vaginal cytology in HIV-infected women after hysterectomy, JAIDS 2004;35:484-491.

Quayle A, Shah M, Cu-Uvin S, Politch J, Chou C, Anderson D, Tuomala R, Crowley-Nowick P, Duerr A. Implications of blood contamination for assessment of local cellular immunity in the endocervix. AIDS Res Hum Retroviruses 2004;20(5):543-6.

Kingkeow D, Heilig C, Costello C, Sennum S, Suriyanon V, Rungruengthanakit V, Taejaroenkul S, Nelson KE, Duerr A. Changes in numbers of lymphocytes and lymphocyte subpopulations in HIV-infected northern Thais. AIDS Res Hum Retroviruses 2004;20:636-41.

Kulczycki A, Kim D, Duerr A, Jamieson J, Macaluso M. The acceptability of the female and male condom: a randomized crossover trial. Perspectives on Sexual and Reproductive Health 2004;36:114-19.

Chen N, Nelson KE, Jenkins F, Suriyanon V, Duerr A, Robison V, Jacobson LP. Seroprevalence of Human Herpesvirus-8 in Northern Thailand. Clin Infect Dis 2004;39:1052-8.

Tohill BC, Heilig CM, Klein RS, Rompalo A, Cu-Uvin S, Brown W, Duerr A. Vaginal flora morphotypic profiles and assessment of bacterial vaginosis in women at risk for HIV infection. Infect Dis in Obstet & Gynecol 2004;12:121-6.


Viscidi R, Ahdieh L, Clayman B, Fox K, Massad L, Cu-Uvin S, Shah KV, Anastos K, Squires K, Duerr A, Jamieson D, Burk R, Klein RS, Minkoff H, Palefsky J, Strickler H, Schuman P, Piessens E, Miotti P. Serum immunoglobulin G response to human papillomavirus type 16 virus like particles in human immunodeficiency virus Type 1 (HIV-1) positive and risk-matched HIV-1 negative women. J Inf Dis 2003;187:194-205.

Lawson ML, Macaluso M, Duerr A, Hortin G, Hammond KR, Blackwell R, Artz L, Bloom A. Partner characteristics, intensity of the intercourse, and semen exposure during use of the female condom. Am J Epi 2003;157:282-8.

Macaluso M, Lawson ML, Hortin G, Duerr A, Hammond KR, Blackwell R, Bloom A. Efficacy of the female condom as a barrier to semen during intercourse. Am J Epi 2003;157:289-97.

Macaluso M, Lawson ML, Duerr A, Hortin G. Macaluso et al. respond to "Condom effectiveness and prostate-specific antigen". Am J Epi 2003;157:301-2.

Duerr A, Heilig CM, Meikle SF, Cu-Uvin S, Klein RS, Rompalo A, Sobel JD for the HER Study Group. Incident and persistent vulvovaginal candidiasis in HIV-infected women: risk factors and severity. Obstet & Gynecol 2003;101:548-56.

Promadej N, Costello C, Wernett M, Kulkani P, Robison V, Suriyanon V, Duerr A, McNicholl J. Broad HIV-specific T-cell responses to conserved HIV-proteins among HIV-seronegative women highly exposed to a single HIV-infected partner. J Infect Dis 2003;178:1053-63.

Duerr A, Jamieson D. Assisted reproduction for HIV-discordant couples. Am J Bioethics 2003;3:45-47.

Kerimova J, Posner SF, Brown YT, Hillis S, Meikle S, Duerr A. High prevalence of self-reported forced sex among internally displaced women in Azerbaijan. Am J Public Health 2003;93:1067-70.

Kulkarni P, Butera S, Duerr A. Resistance to HIV-1 infection - lessons learned from studies of highly exposed persistently seronegative individuals. AIDS Reviews 2003;5:87-103.

Ohmit SE, Sobel JD, Schuman P, Duerr A, Mayer K, A Rompalo A, Klein RS, for The HER Study Group. A longitudinal study of mucosal Candida colonization and candidiasis among HIV-seropositive and at-risk seronegative women. J Infect Dis 2003;188:118-27.

Schuman P, Ohmit SE, Klein RS, Duerr A, Cu-Uvin S, Jamieson D, Anderson D, Shah K. A. longitudinal study of cervical squamous intraepithelial lesions among HIV-seropositive and at-risk seronegative women. J Infect Dis 2003;188:128-36.

Strickler H, Palefsky J, Shah KV, Anastos K, Klein RS, Minkoff H, Duerr A, Massad LS, Celentano D, Hall C, Fazzari M, Cu-Uvin S, Bacon M, Schuman P, Levine A, Durante A, Gange S, Melnick S, Burk R. The weak association of HPV 16 with immune status in HIV-seropositive women. J Nat Cancer Institute 2003;95:1062-71.

Kourtis A, Duerr A. Prevention of perinatal HIV transmission: a review of novel therapies. Expert Opin Investig Drugs 2003;12:1535-44.

Duerr A, Posner S, Gilbert M. Evidence in support of foster care during acute refugee crises. Am J Pub Health 2003; 93:1904-9.

Kourtis A, Butera S, Ibegbu C, Belec L, Duerr A. Breast milk and HIV-1: vector of transmission or vehicle of protection? Lancet Infect Dis 2003;3:786-93.


Jamieson D, Duerr A, Burk R, Klein RS, Paramsothy P, Schuman P, Cu-Uvin S, Shah K, for the HIV Epidemiology Research Study (HERS) Group. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol 2002;186:21-7.

Silverberg MJ; Ahdieh L; Muñoz A; Burk RD; Palefsky J; Greenblatt RM; Massad S; Minkoff H; Piessens E; Muderspach L; Klein RS; Schuman P; Cu-Uvin S; Duerr A; Watts H; Shah KV. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sexually Transmitted Diseases 2002;29(8):427-35.

Utaipat U, Duerr A, Rudolph D, Yang C, Butera S, Lupo D, Pisell T, Tangmunkongvorakul A, Kamtorn N, Nantachit N, Nagachinta T, Suriyanon V, Robison V, Nelson KE, Sittisombut N, Lal RB. Coreceptor utilization of HIV-1 subtype E viral isolates from Thai men with HIV-1-infected and uninfected wives. AIDS and Human Retroviruses 2002; 18:1-11.

Tovanabutra S, Robison V, Wongtrakul J, Sennum S, Suriyanon V, Kingkeow D, Kawichai S, Tanan S, Duerr A, Nelson KE. Male viral load and heterosexual transmission of HIV-1 Subtype E in Northern Thailand. JAIDS 2002;29:275-83.

Bartlett LA, Jamieson DJ, Kahn T, Sultana M, Wilson H, Duerr A. Maternal mortality among Afghan refugees in Pakistan, 1999-2000. Lancet 2002;359:643-9.

Williams S, Flanigan T, Cu-Uvin S, Mayer K, Williams P, Ettore C, Artenstein A, Duerr A, VanCott T. Human immunodeficiency virus (HIV)-specific antibody in cervicovaginal lavage specimens obtained from women infected with HIV type 1. Clin Infect Dis 2002;35:611-17.

Posner SF, Kerimova J, Schmidt J, Hillis S, Meikle S, Lewis J, Duerr A. Differences in welfare and access to care among internally displaced and local women: seven years after relocation in Azerbaijan. Journal of Refugee Studies 2002; 15:296-303.


Duerr A, Kieke B, Warren D, Shah K, Burk R, Piepert JF, Schuman P, Klein RS, for the HER Study. Human papilloma virus (HPV)-associated cervical cytologic abnormalities among women with or at risk for human immunodeficiency virus infection. Am J Obstet Gynecol 2001;184:584-590.

Sobel JD; Ohmit SE; Schuman P; Klein RS; Mayer K; Duerr A; Vazquez JA; Rompalo A; for the HER Study Group. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from HIV seropositive and at-risk seronegative women. J Infect Dis 2001;183:286-93.

Warren D, Klein RS, Sobel J, Kieke B, Brown W, Schuman P, Anderson J, Cu-Uvin S, Mayer K, Jamieson D, Holmberg S, Duerr A. A multicenter study of bacterial vaginosis in women with or at risk for HIV infection. Infect Dis Obstet Gynecol 2001;9:133-41.

Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, Safaeian M, Astemborski J, Daniel R, Shah K. Prevalence, incidence and type-specific persistence of human papillomavirus in HIV-infected and HIV-negative women. J Infect Dis 2001;184:682-90.

Jamieson D, Duerr A, Klein RS, Paramsothy P, Brown W, Cu-Uvin S, Rompalo A, Sobel J for the HIV Epidemiology Research Study (HERS) Group. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol 2001;98:656-63.

Schoenbaum E, Chang CJ, Moore J, Stein M, Warren D, Schuman P, Solomon L, Duerr A. Patterns of condom use and other contraceptive methods by HIV Infected and uninfected women enrolled in the HER study. Clin J Women’s Health 2001;1:115-22.

2000 and earlier

Jamieson DJ, Meikle SF, Hillis SD, Mtsuko D, Mawji S, Duerr A. An evaluation of poor pregnancy outcomes among Burundian refugees in Tanzania. JAMA, 2000; 283(3): 397-402.

Jamieson DJ, Duerr A, Macasaet MA, Peterson HB, Hillis SD. Risk factors for a complicated clinical course among women hospitalized with pelvic inflammatory disease. Infect Dis Ob & Gynecol 2000;8(2):88-93.

Jamieson DJ, Hillis SD, Duerr A, Marchbanks PA, Costello C, Peterson HB, for the US Collaborative Review of Sterilization Working Group. Complications of interval laparoscopic tubal sterilization: Findings from the United States Collaborative Review of Sterilization. Obstet Gynecol 2000;96:997-1002

Nelson K, Ruengruengthanakit K, Margolick J, Suriyanon V, Niyomthai S, Kuntolbutra S, Celentano D, de Boer MA, Nagachinta T, Duerr A. High rates of sexual HIV transmission among couples infected with subtype E HIV: role of STDs and immune compromise. J Infect Dis 1999;180:337-43.

Perl L, Duerr A. Contraception for HIV-infected women. Gynaecology Forum 1999;4:9-12

Schuman P, Sobel JD, Ohmit SE, Mayer KH, Rompalo A, Duerr A, Smith DK, Warren D, Klein RS. Candida colonization and mucosal candidiasis in women living with or at risk for HIV infection. Clin Inf Dis 1998;27:1161-7.

Rugpao S, Nagachinta T, Wanapirak C, Srisomboon J, Tovanabutra S, Yutabootr Y, Chaiyarassamee O, Celentano DD, Nelson KE, Duerr A, Suriyanon V. Gynecologic conditions associated with HIV infection in Thai women. International J of STD and HIV 1998;9:677-82.

Duerr A, Brockman S, Barbosa C, Macasaet M. HIV infection among women of reproductive age. AIDS 1998;12:(3):330-1.

Barbosa C, Macasaet M, Brockman S, Sierra MF, Xia Z, Duerr A. Pelvic inflammatory disease and HIV infection. Obstet Gyn 1997;89(1):65-70.

Clarke L, Duerr A, Yeung K, Brockman S, Barbosa C, Macasaet M. Isolation of cytomegalovirus and herpes simplex virus from upper and lower genital tract specimens obtained from women with pelvic inflammatory disease. J Infect Dis 1997;176(1):286-8.

Duerr A, Sierra MF, Feldman J, Clarke L, Ehrlick I, DeHovitz J. Immune compromise and prevalence of candida vulvovaginitis in human immunodeficiency virus-infected women. Obstet Gyn 1997; 90:252-6.

Nagachinta T, Duerr A, Suriyanon V, Nantachit N, Rugpao S, Wanapirak, C, et al. Risk factors for HIV-1 transmission from seropositive male blood donors to their regular female partners in northern Thailand. AIDS 1997;11:1765-72.

Clarke LM, Duerr A, Feldman J, Sierra MF, Daidone BJ, Landesman SH. Factors associated with cytomegalovirus infection among human immunodeficiency virus type 1-seronegative and -seropositive women from an urban minority community. J Infect Dis 1996;173:77-82.

The International Working Group on Vaginal Microbicides including Recommendations for the development of vaginal microbicides. AIDS 1996;10:UNAIDS1-UNAIDS6.

Reef SE, Levine WC, McNeil MM, Fisher-Hock S, Holmberg SD, Duerr A, Smith D, Sobel JD, Pinner RW. Treatment options for vulvovaginal candidiasis background paper for development of 1993 STD treatment guidelines. Clin Inf Dis 1995; 20(Sup. 1):80-90.

Dowell SF, Toko A, Sita C, Piarroux R, Duerr A, Woodruff BA. Health and nutrition in centers for unaccompanied refugee children: Experience from the 1994 Rwandan refugee crisis. JAMA 1995;273:1802-6.

Macasaet M, Duerr A, Thelmo W, Vernon S, Unger E. Kaposi’s sarcoma presenting as a vulvar mass. Obstet Gynecol 1995;86:695-7.

Kennedy M, Scarlett M, Duerr A, Chu S. Assessing HIV risk among women who have sex with women: scientific and communication issues. J Am Med Women’s Assoc 1995; 50:103-7.

Cohen CR, Duerr A, Pruithithada N, Rugpao S, Hillier S, Garcia P, and Nelson K. Bacterial vaginosis and HIV seroprevalence among female commercial sex workers in Chiang Mai, Thailand, 1992. AIDS 1995;9:1093-7.

Margono F, Jamil M, Garely A, Duerr A, Minkoff H. Resurgence of active tuberculosis among pregnant women. Obstet Gynecol 1994;83:911-14.

Howe J, Minkoff H, and Duerr A. Contraceptives and HIV. AIDS 1994;8:861-71.

Warren D, Duerr A. HIV infection in nonpregnant women: a review of current knowledge. Current Opin. in Obstet & Gynecol 1993;5:527-33.

Duerr A, Pallas D, Solomon F. Molecular analysis of cytoplasmic microtubules in situ: identification of both widespread and specific associated proteins. Cell 1981;24:203-11.

Ben Ze’ev A, Duerr A, Solomon F, Penman S. The outer boundary of the cytoskeleton: a lamina derived from plasma membrane proteins. Cell 1979;17:859-65.

Trifaro JM, Duerr AC. Isolation and characterization of a Golgi-rich fraction from the adrenal medulla. BBA 1976;421:153-67.

Trifaro JM, Duerr A, Pinto JEB. Membranes of the adrenal medulla: comparison between the membranes of the Golgi apparatus and chromaffin granules. Molecular Pharmacology 1976;12:536-45.

Book Chapters

  1. Minkoff H, Duerr A. Obstetric issues: relevance to women and children. In: Pizzo P, Wilfert C, eds. Pediatric AIDS: the challenge of HIV infection in infants, children, and adolescents. 2nd Edition. Baltimore: Williams and Wilkins 1994;773-784.
  2. Duerr A, Howe J. Contraception and HIV. In: Minkoff H, Dehovitz J, Duerr A, eds. HIV infection in women. New York: Raven Press 1995;157-72.
  3. Guinan ME, Duerr A. Human immunodeficiency virus infection in women. In: Wallis, L ed. Textbook of Women’s Health. Philadelphia: Lippincott-Raven 1998;623-30.
  4. Duerr A. HIV infection. In: Family planning methods and practice: Africa. 2nd ed. Atlanta, GA: United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health 1999.
  5. Duerr A, Corey L, Wasserheit J. HIV Vaccines. In: Sexually transmitted diseases. McGraw Hill 2007.
  6. Barnabas R, Duerr A, Wasserheit J, HIV/AIDS vaccine research. In: Public health aspects of HIV/AIDS in low and middle income countries: Epidemiology, prevention and care. Beyrer C, Celentano D, Eds. Springer. 2008.
  7. Geise R, Duerr A. HIV vaccines. In: HIV prevention: A comprehensive Approach. Mayer K, Pizer H, Eds. Elsevier. 2009.
  8. Cassis-Ghavami F, Curlin M, Geise R, Duerr A. HIV vaccines. In: Barrett A, Stanberry L, eds. Vaccines for biodefense and emerging and neglected diseases. Academic Press, 2009

Letters, editorials, and invited monographs

  1. Bulterys M, Chao A, Bugingo G, Dushimimana A, Duerr A. Female to male transmission of HIV. (Let.) Lancet 1989;2(8669):977-8.
  2. Minkoff H, Duerr A, Schwartz R. AIDS in obstetrics and gynecology. ACOG Update. 1992;18(4):1-10.
  3. Centers for Disease Control and Prevention. Tuberculosis among pregnant women—New York City, 1985-1992. MMWR 1993;42:605-12.
  4. Centers for Disease Control and Prevention. Update: AIDS among women—United States, 1994. MMWR 1995;44:81-4.
  5. Duerr A, Warren D, Smith D, Nagachinta T. Contraceptives and HIV transmission. (Let.) Nature Medicine 1997;3:124.
  6. Duerr A, Curtis K, Shelton JD Meirik O. Hormonal contraception and genital-tract shedding of HIV-1-infected cells. (Let.) Lancet 1998;351:294-5.
  7. Jamieson D, Duerr A, Schieve L. Semen processing for HIV-discordant couples. (Let.) Am J Obstet Gynecol 2001;185:1433-4.
  8. Centers for Disease Control and Prevention. Nonoxynol-9 Spermicide Contraception Use - United States, 1999. MMWR 2002;51(18):389-92. Reprinted in JAMA 2002;287:2939
  9. Centers for Disease Control and Prevention, Infant health among Puerto Ricans - Puerto Rico and U.S. Mainland, 1989-2000. MMWR 2003;52:1012-16.
  10. Kim D, Elizaga M, Duerr A. The future of HIV prevention: HIV vaccine efficacy trials. Infectious Disease Clinics of North America 2007;21:201-17.
  11. Duerr A, Corey L. HIV vaccine effectiveness and the mucosal interface. Future HIV Therapy [Editorial] 2007;1(2):127-9.
  12. Duerr A, Altice F, Harries A, Sohn A. Antiretroviral Treatment in Resource-Limited Settings 2012, AIDS Research and Treatment, vol. 2012, Article ID 346708. doi:10.1155/2012/346708

Book edited

  1. Minkoff H, Dehovitz J, Duerr A. HIV infection in women. New York: Raven Press 1995

Special issues edited

  1. Antiretroviral Treatment in Resource-Limited Settings. AIDS Research and Treatment. Published online 2011.


  1. Duerr A. Commentary on Sewankambo N et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997;350:546-50. Posted 4/20/98.
  2. Duerr A. Clinical development: essays from the experts/from the national conference on women and HIV. Pasadena, CA; May 4-7, 1997. JAMA HIV/AIDS.
  3. Jamieson DJ, Duerr A. Commentary on Burns et al. The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. Amer J Obstet Gynecol 1998;178:355-359.
  4. Duerr A, de Boer M. Commentary on Leroy V et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection.

Invited presentations

  1. 1997 Gynecologic infections: challenges and response. National Conference on Women & HIV: Innovation for Care, Policy and Prevention. Los Angeles, CA
  2. 1997 Heterosexual transmission of HIV: Crossing the epithelial barrier. Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology. Las Croabas, PR
  3. 1997 Gynecologic conditions associated with HIV. Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology. Las Croabas, PR
  4. 1997 Use of the female condom for the prevention of STDs. STD update STD/HIV Prevention Training Center of New England
  5. 1998 Gynecologic conditions in HIV positive women, 12th World AIDS Conference, Geneva, Switzerland
  6. 1998 Use of epidemiologic data to study HIV infectivity. University of Padova, Italy
  7. 1998 III International Symposium on AIDS in Women. Sao Paulo, Brazil
  8. 1998 Gynecologic conditions in HIV positive women, International Symposium on AIDS in Women. Sao Paulo, Brazil
  9. 1999 Effect of HAART on cervical dysplasia and vaginitis among HIV-infected women. National Conference on Women and HIV/AIDS. Los Angeles, CA
  10. 1999 Abnormal vaginal cytology among HIV-infected women after hysterectomy. National Conference on Women and HIV/AIDS. Los Angeles, CA
  11. 1999 Use of highly sensitive markers of semen exposure to measure failure of the female condom. Exploring common ground: building a close alliance between family planning and STD/HIV prevention activities. WHO/UNAIDS/UNFPA, Geneva, Switzerland
  12. 2001 HIV and infertility. American Society for Reproductive Medicine. Orlando, FL
  13. 2002 HIV infection in women: implications for clinical care and prevention. Wake Forest University School of Medicine, Winston-Salem, NC
  14. 2002 Assisted reproduction among HIV discordant couples in the US, International AIDS meeting. Barcelona, Spain
  15. 2002 Potential use of the diaphragm for prevention of cervical STD. Diaphragm Renaissance: the role of cervical barriers. Seattle, WA
  16. 2004 HIV vaccine development: a scientific challenge and a public health necessity. American Association for the Advancement of Science Annual Meeting. Seattle, WA
  17. 2004 Correlates of mucosal immune protection: Lessons learned from highly exposed uninfected individuals. AIDS Vaccine 2004. Lausanne, Switzerland
  18. 2005-2011 International careers in preventive medicine. Preventive Medicine 2005, Washington, DC; Preventive Medicine 2006, Reno, NV; Preventive Medicine 2007, Miami, FL; Preventive Medicine 2008, Austin, TX; Preventive Medicine, San Antonio, TX
  19. 2006 HIV vaccine clinical trials: summary of presentations and reflections (Rapporteur-Clinical trials), AIDS Vaccine 2006. Amsterdam, Netherlands
  20. 2006 Update on new HIV vaccine candidates. Global Vaccine Research Forum (sponsored by WHO and Global AIDS Vaccine Initiative). Bangkok, Thailand
  21. 2007 HIV vaccines: new frontiers in vaccine development, Dartmouth-Hitchcock Medical Center AIDS Seminar, Lebanon, New Hampshire (webcast)
  22. 2007 HIV vaccine development: a scientific necessity and a public health challenge, Harborview Medical, HIV seminar, Seattle Washington
  23. 2007 Unexpected results from HVTN 502, a test-of-concept trial of an HIV vaccine, PHS Faculty seminar, Seattle
  24. 2008 Failure of an Ad5-HIV vaccine: Did vaccine-related events lead to increased susceptibility? UW/FHCRC ID Virology Conference, Seattle, WA
  25. 2008 HIV Vaccines, Clinical Keynote Address, [Kentucky] State HIV Conference. Lexington, KY
  26. 2008 Update on HVTN trials. HVTN External Advisory Committee, Boston MA (February), New York (October)
  27. 2009 An update on HIV vaccines: Reflections on unexpected results and future possibilities. “Meeting the Human Immunology Challenge”, Center for Human Immunology Clinical Conference. NIH, Bethesda, MD
  28. 2009 Inducing immune responses to HIV vaccines at mucosal surfaces. University of California, San Francisco (Department of Experimental Medicine), San Francisco, CA
  29. 2012 Treatment for Prevention of HIV Transmission. “International Course of HIV: Pathogenesis, Prevention and Treatment, 2012. The Road Ahead. March 23-24, 2012. Lima Peru